The Company's AGM will be held at 12:00pm on 27 November 2019 at 46 Grafton Street, Manchester M13 9XX.
The Company also announces the intention to propose to shareholders, for approval at the Company's forthcoming AGM, the appointment of RSM UK Audit LLP as its auditor for the year ending 30 June 2020.
This decision follows a competitive tender process which has been overseen by the Audit and Risk Committee. PwC LLP (PwC), the Company's current auditor, undertook and completed the audit for the year ended 30 June 2019. PwC has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company.
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Headlines from Proactive UK newsroom.
Genedrive (LON:GDR) has scored 100% diagnostic sensitivity and 100% specificity in a test of its assay kit to identify babies at risk of hearing loss from the use of antibiotic gentamicin. The clinical study was based on 303 samples.